Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.

The Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include the treatment of edema in patients with chronic kidney disease (CKD), including ...

Furoscix is expected to be available for CKD patients in April 2025. The Food and Drug Administration (FDA) has expanded the approval of Furoscix ® (furosemide injection) to include the treatment ...

The Furoscix 80 mg/10 ml subcutaneous injection is intended for oedema in adult CKD patients, including those with nephrotic ...

Cardiorenal specialist scPharmaceuticals has won US Food and Drug Administration (FDA) approval for its supplemental New Drug Application (sNDA) for Furoscix (furosemide injection) to expand the ...

Objectives In severe heart disease, parenteral administration of loop diuretic is often needed. We present clinical outcomes from episodes of care using subcutaneous continuous subcutaneous infusion ...

Injective (INJ) has experienced a significant decline since reaching its all-time high (ATH) of $53 in March 2024. Since then, the altcoin has dropped by an alarming 73%, with its price hovering near ...

INJ has dropped 73% since its ATH, forming a falling wedge pattern that hinted at a potential bullish breakout. The INJ 3.0 upgrade aims to reduce the supply until 2026, igniting hopes of a price ...

2 Over the past decade, the use of SC furosemide to treat congestion in end-stage heart failure has increased, particularly in the field of palliative care. There is clearly a growing body of ...